Puma Biotechnology
PBYI
77 hedge funds and large institutions have $86.1M invested in Puma Biotechnology in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 22 closing their positions.
391% more call options, than puts
Call options by funds: $1.13M | Put options by funds: $229K
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 59.74% → 59.59% (-0.15%)
13% less funds holding
Funds holding: 88 → 77 (-11)
25% less capital invested
Capital invested by funds: $115M → $86.1M (-$29.3M)
50% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$1.62M |
| 2 |
Millennium Management
New York
|
+$1.16M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$765K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$688K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$669K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$1.35M |
| 2 |
AC
Armistice Capital
New York
|
-$1.27M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.15M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$600K |
| 5 |
Morgan Stanley
New York
|
-$595K |
PBYI Hedge Fund Activity: Q1 2023 in Review
77 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2023, worth a combined $86.1M — down 25% from $115M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PBYI and 11 opened new positions — a net loss of 11 holders — while 19 trimmed existing stakes and 28 added.
The largest buyer was Eversept Partners, adding an estimated $1.62M. The largest seller was Brandywine Global Investment Management, exiting entirely with an estimated $1.35M sold.
- 77 institutional investors held Puma Biotechnology (PBYI) as of Q1 2023, down from 88 in Q4 2022.
- Funds reported $86.1M of Puma Biotechnology stock for Q1 2023, down 25% quarter-over-quarter.
- 11 funds opened new Puma Biotechnology positions in Q1 2023 and 22 closed out, a net change of -11 holders.
- The largest Puma Biotechnology buyer in Q1 2023 was Eversept Partners, an estimated $1.62M added.
- The largest Puma Biotechnology seller in Q1 2023 was Brandywine Global Investment Management, an estimated $1.35M sold.
Based on aggregated 13F filings for Q1 2023.